Luca Piali

Basel, BS 4070, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Translocating gut pathobiont Enterococcus gallinarum induces TH17 and IgG3 anti-RNA-directed autoimmunity in mouse and human.

Translocating gut pathobiont Enterococcus gallinarum induces TH17 and IgG3 anti-RNA-directed autoimmunity in mouse and human.

Journal: Science translational medicine
Published: February 05, 2025

Novel Macrocyclic NLRP3 Inhibitors.

Novel Macrocyclic NLRP3 Inhibitors.

Journal: Journal of medicinal chemistry
Published: November 25, 2024

A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.

A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.

Journal: Clinical and translational medicine
Published: July 31, 2023

Human Th17- and IgG3-associated autoimmunity induced by a translocating gut pathobiont.

Human Th17- and IgG3-associated autoimmunity induced by a translocating gut pathobiont.

Journal: bioRxiv : the preprint server for biology
Published: July 10, 2023

Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125.

Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases: Discovery of ACT-672125.

Journal: Journal of medicinal chemistry
Published: August 15, 2022

Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases.

Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases.

Journal: Journal of medicinal chemistry
Published: August 10, 2022

Translational precision medicine: an industry perspective.

Translational precision medicine: an industry perspective.

Journal: Journal of translational medicine
Published: February 02, 2021

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis.

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis.

Journal: Innovations in clinical neuroscience
Published: June 20, 2019

High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis.

High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis.

Journal: European journal of immunology
Published: August 13, 2018

Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties.

Journal: Pharmacology research & perspectives
Published: August 30, 2017

Expression of checkpoint molecules on myeloid-derived suppressor cells.

Expression of checkpoint molecules on myeloid-derived suppressor cells.

Journal: Immunology letters
Published: August 15, 2017

Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes.

Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes.

Journal: PloS one
Published: June 11, 2013
Showing 1-12 of 12

Last Updated: 09/26/2026